P633H, a novel dual agonist at peroxisome proliferator-activated receptors α and γ, with different anti-diabetic effects in db/db and KK-A y mice

British Journal of Pharmacology

Volumn 157, Issue 5, 2009, Pages 724-735

  Chen, Wei ^a   Zhou, Xin Bo ^a   Liu, Hong Ying ^a   Xu, Cheng ^b   Wang, Li Li ^a   Li, Song ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Insulin resistance; Pancreas; PPAR; Type 2 diabetes mellitus

Indexed keywords

2 [4 (2 FLUOROBENZENESULPHONYL)PIPERAZIN 1 YL] 3 [4 [2 (5 METHYL 2 PHENYLOXAZOL 4 YL) ETHOXY]PHENYL]PROPIONIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANTIDIABETIC AGENT; CHOLESTEROL; FATTY ACID; FENOFIBRATE; GLUCOSE; GW 409544; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; P 633 H; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; FEMALE; FOOD INTAKE; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION; WEIGHT REDUCTION;

3T3-L1 CELLS; ACYL-COA OXIDASE; ADIPOCYTES; ANIMALS; BLOOD GLUCOSE; CELL DIFFERENTIATION; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; FATTY ACID-BINDING PROTEINS; FATTY ACIDS, NONESTERIFIED; FEMALE; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; PANCREAS; PHENYLPROPIONATES; PPAR ALPHA; PPAR GAMMA; RNA, MESSENGER; SULFONAMIDES; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TRIGLYCERIDES;

EID: 70350191821     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00231.x     Document Type: Article

References (29)

1. Bedoucha M, Atzpodien E, Boelsterli UA (2001). Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 35: 17-23. (Pubitemid 32646220)
2. Boden G (2002). Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 5: 545-549. (Pubitemid 40684651)
3. Chen W, Wang LL, Liu HY, Long L, Li S (2008). Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice. Basic Clin Pharmacol Toxicol 103: 240-246.
4. Desvergne B, Michalik L, Wahli W (2004). Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 18: 1321-1332. (Pubitemid 38692172)
5. Ferre P (2004). The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (Suppl. 1): S43-S50.
6. Flordellis CS, Ilias I, Papavassiliou AG (2005). New therapeutic options for the metabolic syndrome: what's next? Trends Endocrinol Metab 16: 254-260. (Pubitemid 41058756)
7. Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV et al. (2000). Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 5: 545-555.
8. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B et al. (2000). Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642. (Pubitemid 30398891)
9. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL et al. (1998). N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41: 5020-5036.
10. Huang H, lida KT, Sone H, Yokoo T, Yamada N, Ajisaka R (2006). The effect of exercise training on adiponectin receptor expression in KKAy obese/diabetic mice. Journal of. Endocrinology 189: 643-653.
11. Hung YJ, Hsieh CH, Pel D, Kuo SW, Lee JT, Wu LY et al. (2005). Rosiglltazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance. Clin Endocrinol (Oxf) 62: 85-91. (Pubitemid 40175288)
12. Iwatsuka H, Shino A, Suzuoki Z (1970). General survey of diabetic features of yellow KK mice. Endocrinol Jpn 17: 23-35.
13. Jeppesen PB, Nordentoft I, Abudula R, Hong J, Hermansen K (2007). Isosteviol as novel oral anti-diabetic agent for treatment of type 2 diabetes and the metabolic syndrome - a in vivo study on diabetic KKAy-mice. Diabetologia 50: S95.
14. Li PP, Shan S, Chen YT, Ning ZQ, Sun SJ, Liu Q et al. (2006). The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br J Pharmacol 148: 610-618. (Pubitemid 43993051)
15. Li S, Zhou XB, Wang LL, Xu C, Ruan CM, Lin CF et al. (2007) Substituted a-piperazinglyphenylpropionic acid derivatives as hPPAR alpha and/or hPPAR gamma agonists. US2007259883A1.
16. Ljung B, Bamberg K, Dahllof B, Kjellstedt A, Oakes ND, Ostling J et al. (2002). AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 43: 1855-1863.
17. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y et al. (1998). A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47: 1841-1847. (Pubitemid 28549189)
18. Pickavance LC, Brand CL, Wassermann K, Wilding JPH (2005). The dual PPAR alpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br f Pharmacol 144: 308-316. (Pubitemid 40313676)
19. Qi C, Zhu Y, Reddy JK (2000). Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 32 (Spring): 187-204.
20. van Raalte DH, Li M, Pritchard PH, Wasan KM (2004). Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 21: 1531-1538. (Pubitemid 41184380)
21. Ramachandran U, Kumar R, Mittal A (2006). Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome. Mini Rev Med Chem 6: 563-573. (Pubitemid 43731183)
22. Ramirez-Zacarias JL, Castro-Munozledo F, Kuri-Harcuch W (1992). Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 97: 493-497.
23. Saltiel AR, Kahn CR (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799-806. (Pubitemid 34000783)
24. Tenenbaum A, Fisman EZ, Motro M (2003). Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovasc Diabetol 2: 4. (Pubitemid 38751109)
25. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T et al. (2005). Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPA-Ralpha, PPARgamma, and their combination. Diabetes 54: 3358-3370. (Pubitemid 43334324)
26. Xu C, Wang LL, Liu HY, Zhou XB, Cao YL, Li S (2006). C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism. Acta Pharmacol Sin 27: 223-228. (Pubitemid 43171162)
27. Yajima K, Hirose H, Fujita H, Seto Y, Fujita H, Ukeda K et al. (2003). Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 284: E966-E971. (Pubitemid 36444032)
28. Yang Y, Shang W, Zhou L, Jiang B, Jin H, Chen M (2007). Emodin with PPARgamma ligand-binding activity promotes adipocyte differentiation and increases glucose uptake in 3T3-L1 cells. Biochem Biophys Res Commun 353: 225-230. (Pubitemid 46014560)
29. Zhang ZY, Jung DY, Ola MS, Linden J, Lanoue KF, Kim JK (2007). Short-term treatment with adenosine A(2B) receptor antagonist improves insulin sensitivity in diabetic KKAy mice. Diabetes 56: A64.